[Federal Register Volume 62, Number 167 (Thursday, August 28, 1997)]
[Notices]
[Page 45667]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22935]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 97N-0221]
Benzodiazepines and Related Substances; Criteria for Scheduling
Recommendations Under the Controlled Substance Act; Notice of Public
Hearing Modification
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) in conjunction with
other Federal agencies is announcing that the part 15 public hearing on
benzodiazepines and related substances originally scheduled for
September 11 and 12, 1997, will be held only on September 11, 1997. The
public hearing will not continue to September 12, 1997. The decision to
forego the second day is based on the limited number of respondents
submitting notices of participation in the hearing.
DATES: The hearing will be held on Thursday September 11, 1997, from 9
a.m. to 4 p.m. The closing date for comments will be October 17, 1997.
ADDRESSES: The public hearing will be held at the Renaissance Hotel,
999 Ninth St. NW., Washington, DC. Comments are to be sent to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Transcripts of the
public hearing may be requested in writing from the Freedom of
Information Office (HFI-35), Food and Drug Administration, 5600 Fishers
Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days
after the hearing, at a cost of 10 cents per page. The transcript of
the public hearing, copies of data and information submitted during the
hearing, and any written comments will be available for review at the
Dockets Management Branch (address above) between 9 a.m. and 4 p.m.,
Monday through Friday.
FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Office of Health
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, rm.
15-22, Rockville, MD 20857, 301-827-1696, FAX 301-443- 0232, e-mail
nreuter@bangate.fda.gov''.
SUPPLEMENTARY INFORMATION:
In a notice published in the Federal Register of June 19, 1997 (62
FR 33418), FDA in conjunction with other Federal agencies announced
that it would convene a part 15 public hearing on benzodiazepines and
related substances. The public hearing was scheduled for Thursday,
September 11, 1997 and part of Friday, September 12, 1997.
Persons who wished to participate in the hearing were asked to file
a notice of participation with the Dockets Management Branch (address
above) on or before August 14, 1997. In response to that notice, eight
individuals representing various organizations indicated their interest
in participating in the hearing. FDA, along with the other
participating agencies, have determined that the number of individuals
indicating an interest in participating in the hearing can be
accommodated in one full day and that there is no need to continue the
hearing to the second day. Therefore, the public hearing will be held
at the address above from approximately 9 a.m. until 4 p.m. on
September 11, 1997.
Interested parties may still sign up to participate in the hearing.
The June 19, 1997, notice included a provision whereby persons may give
oral notice of participation by calling Nicholas Reuter (telephone
number above) no later than August 29, 1997. This notice extends until
September 3, 1997, the opportunity to give oral notice of
participation. Those persons who give oral notice of participation
should also submit written notice containing the information described
above to the Dockets Management Branch by the close of business
September 8, 1997.
Dated: August 22, 1997.
William B. Schultz,
Deputy Commissioner for Policy.
[FR Doc. 97-22935 Filed 8-25-97; 11:56 am]
BILLING CODE 4160-01-F
